Although these off-target effects contribute to the antitumor efficacy of BTK inhibitors, they are also associated with a range of adverse events, including hypertension, atrial fibrillation, bleeding complications, and impaired macrophage phagocytosis (Gabizon and London, 2020; Borge et al., 2015). The gene discussed is BTK; the disease is atrial fibrillation.